Tak-379
Diabetes Mellitus
TakedaPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
44 Active assets in the Diabetes Mellitus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Metformin Erbil Polytechnic University | Phase 4 | A |
Pioglitazone Milton S. Hershey Medical Center | Phase 4 | BBB |
Alogliptin Takeda | Phase 3 | BBB |
Glibenclamide Takeda | Phase 4 | BBB |
Acetylsalicylic Acid Region Skane | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →